EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study

Clément Bolognini iD, Antoine Falcoz, Pauline Simon, Fabien Calcagno iD, Alice Hervieu, Nicolas Isambert, Isabelle Desmoulins, Sylvain Causeret iD, David Thibouw, Elsa Kalbacher, Guillaume Meynard iD, Dewi Vernerey und 1 weitere

Cancers · 30.10.2026 · 18 (21) · 3497

DOI: 10.3390/cancers18213497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 30.10.2026. Verfasst von Clément Bolognini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Besançon University Hospital (CHU Jean Minjoz), 25000 Besançon, France. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Metronomic cyclophosphamide (MCP) is sometimes used for advanced soft-tissue sarcoma (STS) when standard therapies are unsuitable. We assessed its activity and safety in routine practice.

Methods

This French three-center retrospective study included 60 adults with unresectable or metastatic STS who started MCP in 2008–2021. Patients received oral cyclophosphamide 50 mg twice daily on days 1–7 of 14-day cycles; 12 (20%) also received prednisolone during treatment weeks. The primary endpoint was progression-free survival (PFS).

Results

Median age was 70 years; 55% had ECOG performance status 2–3. Median PFS and overall survival (OS) were 2.6 months (95% CI, 1.8–3.6) and 6.4 months (95% CI, 4.2–9.3), respectively. The objective response rate was 5.0% (3/60; exact 95% CI, 1.0–13.9%) and the disease control rate was 21.7% (13/60; exact 95% CI, 12.1–34.2%); ten patients (16.7%) were not radiologically evaluable. In 21 patients aged >65 years treated in the first- or second-line setting, median PFS and OS were 3.2 and 7.7 months. Treatment-related adverse events were documented in 16 patients (26.7%), with no grade ≥3 events recorded.

Conclusions

Intermittent low-dose MCP showed limited antitumor activity but favorable clinician-documented short-term tolerability in this multicenter cohort. Alongside prospective evidence, the results do not support routine use in unselected patients. MCP may retain an individualized palliative role when established systemic therapy is unsuitable.

Schlagwörter

Stichwörter der Autor:innen

cyclophosphamidegeriatric oncologymetronomic chemotherapyreal-world evidenceretrospective studysoft-tissue sarcoma

Autor:innen und Institutionen

  • Department of Medical Oncology, Besançon University Hospital (CHU Jean Minjoz), 25000 Besançon, France.
  • Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
  • Methodology and Quality of Life in Oncology Unit, Besançon University Hospital, 25000 Besançon, France.
  • Department of Pediatric Oncology and Hematology, Besançon University Hospital, 25000 Besançon, France.
  • Département D'oncologie Médicale, Chirurgie et Radiothérapie, Centre Georges-François Leclerc, Unicancer, Université Bourgogne Europe, 21000 Dijon, France.
  • Department of Medical Oncology, Poitiers University Hospital, 86000 Poitiers, France.

ORCID-Profile: Clément Bolognini, Fabien Calcagno, Sylvain Causeret, Guillaume Meynard, Loïc Chaigneau

Zitieren

APA

Bolognini, C., Falcoz, A., Simon, P., Calcagno, F., Hervieu, A., Isambert, N., Desmoulins, I., Causeret, S., Thibouw, D., Kalbacher, E., Meynard, G., Vernerey, D., & Chaigneau, L. (2026). Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study. Cancers, 18(21), 3497. https://doi.org/10.3390/cancers18213497

Vancouver

Bolognini C, Falcoz A, Simon P, Calcagno F, Hervieu A, Isambert N, et al. Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study. Cancers. 2026;18(21):3497. doi:10.3390/cancers18213497

BibTeX
@article{Bolognini2026,
  author = {Bolognini, Clément and Falcoz, Antoine and Simon, Pauline and Calcagno, Fabien and Hervieu, Alice and Isambert, Nicolas and Desmoulins, Isabelle and Causeret, Sylvain and Thibouw, David and Kalbacher, Elsa and Meynard, Guillaume and Vernerey, Dewi and Chaigneau, Loïc},
  title = {Real-World Activity and Safety of Metronomic Cyclophosphamide in Advanced Soft-Tissue Sarcoma: The Multicenter MeRCY Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3497},
  doi = {10.3390/cancers18213497}
}
Kostenlos starten →